MedLife launches the EarlyCDT® test, which allows early detection of lung cancer by identifying specific autoantibodies, available in all its units.
Delia Niculescu
Current Affairs
foto:shutterstock
Always see our news on Google
MedLife Group, the leading private healthcare provider in Romania, has introduced the EarlyCDT® test, a blood-based immunologic test for the early detection of lung cancer. It identifies autoantibodies produced by the body up to 4 years before visible lesions appear. The test is non-invasive and is mainly targeted at people with risk factors, with a turnaround time of about 15 days. Studies show that the use of this test reduces late-stage diagnoses by 36%, increasing the chances of survival. MedLife reaffirms its commitment to innovation in laboratory medicine.
Sources
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Inovație în medicina de laborator: MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Latest News
08:45
Donald Trump will visit Ireland for two days / Bilateral meetings and participation in the golf tournament on the US president’s agenda
08:18
Prime Minister Ulf Kristersson's warning ahead of Sweden's first elections since joining NATO: A left-wing victory would jeopardize the country's missions within NATO
07:49
A passenger train derailed in Normandy, France: At least 44 people were injured
07:30
A deployment of European troops in Ukraine would mean “a war against Russia,” Vladimir Putin claims
07:11
Volodymyr Zelenskyy asks Donald Trump to urgently impose severe sanctions against Russia: “Sometimes I don’t understand why decisions cannot be made quickly”
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
